Biomedicines (Jul 2023)

Impact of HPV-16 Lineages Infection in Response to Radio-Chemotherapy in Cervical Cancer

  • Fábio Vidal de Figueiredo,
  • Gerusinete Rodrigues Bastos dos Santos,
  • Flávia Castello Branco Vidal,
  • Marcos Antonio Custódio Neto da Silva,
  • Rodrigo Lopes da Silva,
  • Zulmira da Silva Batista,
  • Marcelo Souza de Andrade,
  • Maria do Carmo Lacerda Barbosa,
  • Anna Cyntia Brandão Nascimento Maniçoba,
  • Mayara Cristina Pinto da Silva,
  • Maria do Desterro Soares Brandão Nascimento

DOI
https://doi.org/10.3390/biomedicines11072069
Journal volume & issue
Vol. 11, no. 7
p. 2069

Abstract

Read online

Background: HPV is strongly related to cervical cancer. HPV lineages can contribute to a response to cervical cancer therapy. The aim of this research was to estimate the frequency of human papillomavirus (HPV)-16 lineages in specimens of cervical cancer, relate the pathological factors in these variants, and assess their response to treatment with radical chemoradiotherapy. Methods: Samples of cervical cancer were collected from women who were referred to a reference cancer hospital to test the presence of human papillomavirus-type DNA. The standard protocol of this service consisted of cisplatin-based chemotherapy of 40 mg/m2, plus conventional pelvic irradiation in doses of 45–50.4 Gy and high dose-rate brachytherapy of 28–30 Gy to Point A. The response to chemotherapy was evaluated after three months in patients with the HPV-16 lineage. Results: HPV DNA was detected in 104 (88.1%) of the 118 patients. HPV-16 was present in 63 patients (53%). Lineages of HPV-16 were identified in 57 patients and comprised 33 instances of (57.8%) lineage A, 2 instances of lineage B (3.5%), 2 instances of lineage C (3.5%), and 20 instances of (35.0%) lineage D. The median age of the patients was 48.4 years (range 25–85 years). Squamous cell carcinoma was detected 48 times (84.2%). Adenocarcinoma was more likely to occur in lineage D, as three of the four cases occurred in this lineage. A total of 11 patients with the HPV-16 variant were treated with chemoradiotherapy. After three months, it was observed that nine of the eleven patients (81.8%) achieved a complete response, five with the lineage A type, two with the lineage C type, and two with the lineage D type. The two cases of partial response and disease progression, one of each, occurred in lineage A. Conclusions: In addition to the small number of patients and HPV variants, we noticed a better response in patients with the HPV-16 lineage A. Increasing the sample size could be helpful to better assess the impact of HPV variants on cervical cancer treatment.

Keywords